Alfons A Den Broeder

List of Publications by Year
in descending order

131 papers	4,951 citations	126907 33 h-index	98798 67 g-index
133 all docs	133 docs citations	133 times ranked	5523 citing authors

#	Article	IF	Citations
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
2	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis and Rheumatology, 2018, 70, 60-68.	5.6	142
3	A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Annals of the Rheumatic Diseases, 2012, 71, 845-850.	0.9	141
4	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ, The, 2015, 350, h1389-h1389.	6.0	135
5	Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Annals of the Rheumatic Diseases, 2013, 72, 895-900.	0.9	124
6	The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2015, 74, 998-1003.	0.9	121
7	Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Annals of the Rheumatic Diseases, 2013, 72, 1800-1805.	0.9	106
8	Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology, 2011, 50, 196-203.	1.9	103
9	Open‐Label, Non‐Mandatory Transitioning From Originator Etanercept to Biosimilar <scp>SB</scp>4. Arthritis and Rheumatology, 2018, 70, 1408-1418.	5.6	90
10	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1849-1854.	0.9	88
11	Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Annals of the Rheumatic Diseases, 2017, 76, 1693-1699.	0.9	82
12	The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study. BMC Musculoskeletal Disorders, 2012, 13, 117.	1.9	75
13	Validation Study of Existing Gene Expression Signatures for Anti-TNF Treatment in Patients with Rheumatoid Arthritis. PLoS ONE, 2012, 7, e33199.	2.5	61
14	Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. The Cochrane Library, 2014, , CD010455.	2.8	61
15	Longitudinal impact of joint pain comorbidity on quality of life and activity levels in knee osteoarthritis: data from the Osteoarthritis Initiative. Rheumatology, 2013, 52, 543-546.	1.9	60
16	Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. Arthritis and Rheumatology, 2017, 69, 301-308.	5.6	56
17	Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: A randomized controlled trial. Patient Education and Counseling, 2014, 94, 356-361.	2.2	55
18	Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskeletal Disorders, 2013, 14, 350.	1.9	53

#	Article	IF	Citations
19	Time to achieve remission determines time to be in remission. Arthritis Research and Therapy, 2010, 12, R97.	3.5	52
20	The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 2171-2177.	2.0	48
21	Joint–pain comorbidity, health status, and medication use in hip and knee osteoarthritis: A cross–sectional study. Arthritis Care and Research, 2012, 64, 54-58.	3.4	47
22	Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology, 2013, 52, 1500-1508.	1.9	47
23	Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. Patient Preference and Adherence, 2014, 8, 1635.	1.8	46
24	Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases, 2016, 75, 1939-1944.	0.9	46
25	De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?. Best Practice and Research in Clinical Rheumatology, 2015, 29, 550-565.	3.3	45
26	Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology, 2010, 49, 1801-1803.	1.9	44
27	Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial. Annals of the Rheumatic Diseases, 2019, 78, annrheumdis-2018-214104.	0.9	43
28	Fatigue in knee and hip osteoarthritis: the role of pain and physical function. Rheumatology, 2011, 50, 1894-1900.	1.9	41
29	Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskeletal Disorders, 2013, 14, 299.	1.9	39
30	Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Annals of the Rheumatic Diseases, 2017, 76, 1716-1722.	0.9	39
31	Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology, 2011, 50, 1320-1330.	1.9	37
32	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study. BMC Musculoskeletal Disorders, 2011, 12, 12.	1.9	35
33	bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatology and Therapy, 2017, 4, 1-24.	2.3	34
34	Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. The Cochrane Library, 2019, 2019, CD010455.	2.8	33
35	Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Annals of the Rheumatic Diseases, 2011, 70, 877-878.	0.9	32
36	The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 1191-1196.	0.9	32

#	ARTICLE	IF	CITATIONS
37	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non‑)response to infliximab in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2013, 76, 939-945.	2.4	32
38	Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis. JAMA Dermatology, 2020, 156, 393.	4.1	29
39	Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open, 2018, 4, e000654.	3.8	28
40	Should We Redefine Treatment Targets in Rheumatoid Arthritis? Low Disease Activity Is Sufficiently Strict for Patients Who Are Anticitrullinated Protein Antibody-negative. Journal of Rheumatology, 2013, 40, 1268-1274.	2.0	26
41	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskeletal Disorders, 2012, 13, 184.	1.9	25
42	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. Journal of Rheumatology, 2017, 44, 1536-1543.	2.0	25
43	Effectiveness of a Third Tumor Necrosis Factor-α-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2355-2361.	2.0	23
44	Ultrasonographic predictors for clinical and radiological progression in knee osteoarthritis after 2 years of follow-up. Rheumatology, 2015, 54, 2000-2003.	1.9	23
45	The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. Rheumatology, 2018, 57, 1947-1955.	1.9	23
46	Exploring longitudinal associations of histologically assessed inflammation with symptoms and radiographic damage in knee osteoarthritis: combined results of three prospective cohort studies. Osteoarthritis and Cartilage, 2019, 27, 71-79.	1.3	22
47	Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Research and Therapy, 2020, 22, 97.	3.5	22
48	Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study. Journal of Rheumatology, 2017, 44, 1325-1330.	2.0	21
49	The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review. Rheumatology, 2019, 58, 1907-1922.	1.9	21
50	Non-pharmacological care for patients with generalized osteoarthritis: design of a randomized clinical trial. BMC Musculoskeletal Disorders, 2010, 11, 142.	1.9	20
51	A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Rheumatology, 2017, 56, 973-980.	1.9	20
52	Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. Best Practice and Research in Clinical Rheumatology, 2015, 29, 543-549.	3.3	18
53	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 403.	1.6	18
54	Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. Current Opinion in Rheumatology, 2018, 30, 266-275.	4.3	18

#	ARTICLE	IF	CITATIONS
55	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. Patient Education and Counseling, 2012, 89, 143-151.	2.2	17
56	Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 843-857.	3.3	17
57	Feasibility and potential effectiveness of a non-pharmacological multidisciplinary care programme for persons with generalised osteoarthritis: a randomised, multiple-baseline single-case study. BMJ Open, 2012, 2, e001161.	1.9	15
58	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 2260-2261.	0.9	15
59	Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. BMC Dermatology, 2017, 17, 6.	2.1	15
60	Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists. Arthritis Care and Research, 2016, 68, 562-569.	3.4	14
61	The effects of methotrexate and hydroxychloroquine combination therapy<i>vs</i>methotrexate monotherapy in early rheumatoid arthritis patients. Rheumatology, 2019, 58, 131-134.	1.9	14
62	NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium. Scientific Reports, 2020, 10, 4316.	3.3	14
63	Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. Trials, 2020, 21, 90.	1.6	14
64	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. Pharmacogenomics, 2019, 20, 85-93.	1.3	13
65	Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. Acta Dermato-Venereologica, 2020, 100, adv00340.	1.3	13
66	ï»¿Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key. Annals of the Rheumatic Diseases, 2019, 78, 141-142.	0.9	12
67	Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model. Journal of Rheumatology, 2015, 42, 398-404.	2.0	11
68	Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases. Journal of Rheumatology, 2018, 45, 122-127.	2.0	10
69	Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients. Scientific Reports, 2018, 8, 14050.	3.3	10
70	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Pharmacogenomics Journal, 2019, 19, 83-96.	2.0	10
71	Long-term efficacy of low-dose radiation therapy on symptoms in patients with knee and hand osteoarthritis: follow-up results of two parallel randomised, sham-controlled trials. Lancet Rheumatology, The, 2020, 2, e42-e49.	3.9	10
72	Measuring Flares in Rheumatoid Arthritis. (Why) Do We Need Validated Criteria?. Journal of Rheumatology, 2014, 41, 189-191.	2.0	9

#	Article	IF	Citations
73	Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Annals of the Rheumatic Diseases, 2022, 81, 1392-1399.	0.9	9
74	Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 2.	3.5	8
75	Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?. Rheumatology, 2009, 48, 1247-1253.	1.9	7
76	Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. Scientific Reports, 2019, 9, 14812.	3.3	7
77	Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study. Scandinavian Journal of Rheumatology, 2019, 48, 439-447.	1.1	7
78	Implementing Psoriatic Arthritis Disease Activity Score–guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?. Rheumatology, 2019, 58, 2330-2331.	1.9	7
79	The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychology Review, 2023, 17, 148-168.	8.6	7
80	Effectiveness and cost‐effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials. Physiotherapy Research International, 2022, 27, e1933.	1.5	7
81	Nephrotic syndrome associated with anti-tumor necrosis factor ? therapy in a patient with rheumatoid arthritis: Comment on the article by Charles et al. Arthritis and Rheumatism, 2002, 46, 1691-1693.	6.7	6
82	What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?. RMD Open, 2017, 3, e000327.	3.8	6
83	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). Trials, 2020, 21, 155.	1.6	6
84	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. Frontiers in Immunology, 2021, 12, 672255.	4.8	6
85	Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions. Arthritis Research and Therapy, 2022, 24, 74.	3.5	6
86	Improvement in deployment of MRI of the sacroiliac joints in patients suspected for spondyloarthritis using a targeted intervention: a case study. Rheumatology, 2013, 52, 933-938.	1.9	5
87	Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report. BMC Infectious Diseases, 2014, 14, 330.	2.9	5
88	Reactive Rather than Proactive Diabetes Management in the Perioperative Period. Hormone and Metabolic Research, 2017, 49, 527-533.	1.5	5
89	THU0215…Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. , 2018, , .		5
90	Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent <i>et al</i>. Annals of the Rheumatic Diseases, 2013, 72, e14-e14.	0.9	4

#	Article	IF	Citations
91	Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?. Clinical and Experimental Rheumatology, 2021, 39, 32-37.	0.8	4
92	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. Journal of Dermatological Treatment, 2022, 33, 2680-2684.	2.2	4
93	Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. Rheumatology, 2022, 62, 330-334.	1.9	4
94	SAT0025â€¦Shift in Genetic Composition of an IL-32 Promoter Polymorphism Resuls in a Higher Cytokine Production in RA Patients. Annals of the Rheumatic Diseases, 2015, 74, 657.3-658.	0.9	3
95	Measurement Properties of the Polymyalgia Rheumatica Activity Score: A Systematic Literature Review. Journal of Rheumatology, 2022, 49, 627-634.	2.0	3
96	Age-Related Health Hazards in Old Patients with First-Time Referral to a Rheumatologist: A Descriptive Study. Arthritis, 2011, 2011, 1-7.	2.0	2
97	THU0228â€¦Validity of Omeract Preliminary Flare Questions in a Randomized Controlled Trial, that Assesses Impact of Disease Activity Guided Down-Titration of Anti-TNF Treatment in Rheumatoid Arthritis Patients in Low Disease Activity. Annals of the Rheumatic Diseases, 2014, 73, 260.3-261.	0.9	2
98	Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshidaet al. Annals of the Rheumatic Diseases, 2014, 73, e4-e4.	0.9	2
99	AB0246â€¦Predictive Value of a Multi-Biomarker Disease Activity Score for Successful Dose Reduction of TNF Inhibitors in Rheumatoid Arthritis: Results of the Dress Study. Annals of the Rheumatic Diseases, 2015, 74, 973.3-974.	0.9	2
100	NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 243-249.	1.1	2
101	Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial. Trials, 2022, 23, .	1.6	2
102	AB0247â€¦Associations of a Multi-Biomarker Disease Activity Score with Clinical and Radiographic Parameters in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 974.1-974.	0.9	1
103	THU0058â€¦Prediction of Successful Dose Reduction or Discontinuation of Biologics in Patients with Rheumatoid Arthritis: A Systematic Review. Annals of the Rheumatic Diseases, 2016, 75, 198.3-199.	0.9	1
104	AB0342â€¦Study on Abatacept and Tocilizumab Attenuation (SONATA) in Rheumatoid Arthritis Patients: A Retrospective, Explorative Cohort Study. Annals of the Rheumatic Diseases, 2016, 75, 1019.1-1019.	0.9	1
105	Comment on lâ€™Ami <i>et al</i> titled â€™Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'. Annals of the Rheumatic Diseases, 2018, 77, e67-e67.	0.9	1
106	Response to: â€˜Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritisâ€™ by Wu<i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e25-e25.	0.9	1
107	OP0017â€¦VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR ANTI-TNF DRUG RESPONSE IN RHEUMATOID ARTHRITIS: A META-ANALYSIS OF THREE LARGE COHORTS. Annals of the Rheumatic Diseases, 2021, 80, 9.2-10.	0.9	1
108	Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36, 140-143.	0.8	1

#	Article	IF	Citations
109	Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 367-372.	0.8	1
110	557 EVIDENCE-BASED TAILORED CONSERVATIVE TREATMENT OF KNEE AND HIP OA: BETWEEN KNOWING AND DOING. Osteoarthritis and Cartilage, 2010, 18, S249-S250.	1.3	0
111	AB0324â€¦Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity: a pilot study. Annals of the Rheumatic Diseases, 2013, 72, A886.2-A886.	0.9	0
112	OP0116â€¦Cost-effectiveness and cost-utility analysis of treat-to-target versus usual care in early rheumatoid arthritis: Results of the dream registry. Annals of the Rheumatic Diseases, 2013, 71, 92.2-92.	0.9	0
113	THU0208â€¦Criteria for Clinical Important Worsening in Knee and Hip Osteoarthritis: A First Development and Validation Round. Annals of the Rheumatic Diseases, 2014, 73, 253.3-254.	0.9	0
114	OP0140-HPRâ€¦Preliminary Results of A Randomized Clinical TRIAL Comparing the Effectiveness of A Non-Pharmacological Multidisciplinary Group-Based Treatment Program with A Telephone Monitored Program on Daily Function in Patients with Generalized Osteoarthritis. Annals of the Rheumatic Diseases, 2014, 73, 113.2-113.	0.9	0
115	OP0005-HPRâ€¦Perceived Need to Take Medication is Associated with Medication Non-Adherence in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 61.2-61.	0.9	0
116	Preface. Best Practice and Research in Clinical Rheumatology, 2015, 29, 525-526.	3.3	0
117	How to define worsening in osteoarthritis? Development and validation of preliminary criteria for clinically important worsening in knee and hip osteoarthritis. Osteoarthritis and Cartilage, 2015, 23, A348.	1.3	0
118	Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients. Value in Health, 2015, 18, A647-A648.	0.3	0
119	Reply. Arthritis Care and Research, 2016, 68, 1051-1051.	3.4	0
120	FRI0586â€¦The Effects of An Educational Meeting and Subsequent Computer Reminders on The Ordering of Laboratory Tests by Rheumatologists: An Interrupted Time Series Analysis. Annals of the Rheumatic Diseases, 2016, 75, 654.1-654.	0.9	0
121	THU0142â€¦High Similarity between ex-vivo Inhibited Cytokine Profiling by Golimumab and Adalimumab as A Putative Explanation for Inferior Treatment Response To Golimumab after Adalimumab Failure in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 232.3-233.	0.9	0
122	The value of routine creatine kinase and thyroid stimulating hormone testing in patients with suspected fibromyalgia: a cross-sectional study. Rheumatology, 2016, 55, 1273-1276.	1.9	0
123	FRI0223â€¦Anti-ccp is an independent predictor of 12-month eular response in patients with ra treated with abatacept. , 2017, , .		0
124	SAT0132â€¦The rheumatoid arthritis flare questionnaire (RA-FQ): results of rasch analysis and feedback on real-world applications from international RA patients and clinicians. , 2017, , .		0
125	THU0695â€¦The RA FLARE questionnaire (RA-FQ) is responsive to change in ra symptoms and impacts in clinical and observational trials. , 2017, , .		0
126	P078â€¦A genetic variant of IL-32 is associated with the ex vivo cytokine production of ANTI-TNF treated pbmcs isolated from rheumatoid arthritis patients. , 2018, , .		0

#	Article	IF	Citations
127	Response to: 'Is it time to redefine the role of low-dose radiotherapy for benign disease?' by Montero <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e35-e35.	0.9	0
128	If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling Study. Journal of Rheumatology, 2021, 48, 473-475.	2.0	0
129	AB0873-HPRâ€¦EFFECTIVENESS AND COST-EFFECTIVENESS OF LONGSTANDING EXERCISE THERAPY VERSUS USUAL CARE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR RHEUMATOID ARTHRITIS: THE PROTOCOLS OF TWO PARALLEL RANDOMIZED CONTROLLED TRIALS. Annals of the Rheumatic Diseases, 2021, 80, 1460-1461.	0.9	0
130	Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis. Clinical and Experimental Rheumatology, 2019, 37, 414-421.	0.8	0
131	Seasonal influence on incidence of polymyalgia rheumatica: winter might be coming. Clinical and Experimental Rheumatology, 2021, 39 Suppl 128, 19-20.	0.8	0